Journal: Pigment Cell & Melanoma Research

Article Title: Allele‐Specific GNAQ Q209 Mutations Reveal Context‐Dependent Oncogenic Programs in Uveal Melanoma

doi: 10.1111/pcmr.70121

Figure Lengend Snippet: Q209R preferentially engages FAK‐YAP signaling. (A) Western blot analysis of GNAQ, BAP1, Melan‐A, p‐ERK1/2 (Thr202/Tyr204), ERK1/2, FRA1, p‐AKT (Ser473), AKT, p‐4EBP1 (Ser65), and 4EBP1 expression in mouse UM cell lines harboring GNAQ Q209R or GNAQ Q209L . HSP90 was used as an internal loading control. (B) Quantification of the relative ratio between p‐AKT (Ser473) and AKT in Q209R and Q209L UM cell lines from (A). (C) Quantification of the relative ratio between p‐4EBP1 (Ser65) and 4EBP1 in Q209R and Q209L UM cell lines from (A). (D) Western blot analysis of p‐FAK (Tyr397), FAK, p‐YAP (Ser127), and YAP in mouse UM cell lines harboring GNAQ Q209R or GNAQ Q209L . HSP90 was used as an internal loading control. (E) Quantification of the relative ratio between p‐FAK (Tyr397) and FAK in Q209R and Q209L UM cell lines from (D). (F) Quantification of the relative ratio between p‐YAP (Ser127) and YAP in Q209R and Q209L UM cell lines from (D). Orthotopic tumor‐derived cell lines (QBM12.1 [Q209R], QBM12.3 [Q209R], QBM24 [Q209R], QBM45 [Q209L], QBM47 [Q209L]) and liver metastatic lines (QBM12L [Q209R], QBM12L2 [Q209R], QBM51L [Q209L], QBM53L [Q209L]) were used in A–F. (G) Representative IHC images showing YAP expression in primary tumors from Gnaq CA ; Bap1 CKO ; Myc CKI mice harboring either GNAQ Q209R or GNAQ Q209L . (H) Quantification of the nuclear‐to‐cytoplasmic YAP intensity ratio (H‐score) among primary tumors from Gnaq CA ; Bap1 CKO ; Myc CKI mice harboring either GNAQ Q209R or GNAQ Q209L . (I) Representative IHC images showing YAP expression in liver metastasis derived from intrasplenic transplantation of mouse UM cell lines harboring GNAQ Q209R or GNAQ Q209L . (J) Quantification of nuclear YAP intensity (H‐score) among liver metastasis derived from intrasplenic transplantation of mouse UM cell lines harboring GNAQ Q209R or GNAQ Q209L .

Article Snippet: Antibodies against GNAQ (CST, #14373, RRID:AB_2665457), BAP1 (Abcam, ab255611), Melan‐A (Abcam, ab210546, RRID:AB_2889292), ERK1/2 (CST, #4695, RRID:AB_390779), p‐ERK1/2 (Thr202/Tyr204) (CST, #4370, RRID:AB_2315112), FRA1 (Abcam, ab252421, RRID:AB_2904513), AKT (CST, #4691, RRID:AB_915783), p‐AKT (Ser473) (CST, #4060, RRID:AB_2315049), p‐FAK (Tyr397) (CST, #8556, RRID:AB_10891442), FAK (CST, #3285, RRID:AB_2269034), 4E‐BP1 (CST, #9452, RRID:AB_331692), p‐4E‐BP1 (Ser65; CST, #9451, RRID:AB_330947), YAP (CST, #4912, RRID:AB_2218911), and p‐YAP (Ser127) (CST, #4911, RRID:AB_2218913) were used at 1:1000 as indicated.

Techniques: Western Blot, Analysis, Expressing, Control, Derivative Assay, Transplantation Assay

Journal: Pigment Cell & Melanoma Research

Article Title: Allele‐Specific GNAQ Q209 Mutations Reveal Context‐Dependent Oncogenic Programs in Uveal Melanoma

doi: 10.1111/pcmr.70121

Figure Lengend Snippet: Q209R preferentially engages FAK‐YAP signaling. (A) Western blot analysis of GNAQ, BAP1, Melan‐A, p‐ERK1/2 (Thr202/Tyr204), ERK1/2, FRA1, p‐AKT (Ser473), AKT, p‐4EBP1 (Ser65), and 4EBP1 expression in mouse UM cell lines harboring GNAQ Q209R or GNAQ Q209L . HSP90 was used as an internal loading control. (B) Quantification of the relative ratio between p‐AKT (Ser473) and AKT in Q209R and Q209L UM cell lines from (A). (C) Quantification of the relative ratio between p‐4EBP1 (Ser65) and 4EBP1 in Q209R and Q209L UM cell lines from (A). (D) Western blot analysis of p‐FAK (Tyr397), FAK, p‐YAP (Ser127), and YAP in mouse UM cell lines harboring GNAQ Q209R or GNAQ Q209L . HSP90 was used as an internal loading control. (E) Quantification of the relative ratio between p‐FAK (Tyr397) and FAK in Q209R and Q209L UM cell lines from (D). (F) Quantification of the relative ratio between p‐YAP (Ser127) and YAP in Q209R and Q209L UM cell lines from (D). Orthotopic tumor‐derived cell lines (QBM12.1 [Q209R], QBM12.3 [Q209R], QBM24 [Q209R], QBM45 [Q209L], QBM47 [Q209L]) and liver metastatic lines (QBM12L [Q209R], QBM12L2 [Q209R], QBM51L [Q209L], QBM53L [Q209L]) were used in A–F. (G) Representative IHC images showing YAP expression in primary tumors from Gnaq CA ; Bap1 CKO ; Myc CKI mice harboring either GNAQ Q209R or GNAQ Q209L . (H) Quantification of the nuclear‐to‐cytoplasmic YAP intensity ratio (H‐score) among primary tumors from Gnaq CA ; Bap1 CKO ; Myc CKI mice harboring either GNAQ Q209R or GNAQ Q209L . (I) Representative IHC images showing YAP expression in liver metastasis derived from intrasplenic transplantation of mouse UM cell lines harboring GNAQ Q209R or GNAQ Q209L . (J) Quantification of nuclear YAP intensity (H‐score) among liver metastasis derived from intrasplenic transplantation of mouse UM cell lines harboring GNAQ Q209R or GNAQ Q209L .

Article Snippet: Antibodies against GNAQ (CST, #14373, RRID:AB_2665457), BAP1 (Abcam, ab255611), Melan‐A (Abcam, ab210546, RRID:AB_2889292), ERK1/2 (CST, #4695, RRID:AB_390779), p‐ERK1/2 (Thr202/Tyr204) (CST, #4370, RRID:AB_2315112), FRA1 (Abcam, ab252421, RRID:AB_2904513), AKT (CST, #4691, RRID:AB_915783), p‐AKT (Ser473) (CST, #4060, RRID:AB_2315049), p‐FAK (Tyr397) (CST, #8556, RRID:AB_10891442), FAK (CST, #3285, RRID:AB_2269034), 4E‐BP1 (CST, #9452, RRID:AB_331692), p‐4E‐BP1 (Ser65; CST, #9451, RRID:AB_330947), YAP (CST, #4912, RRID:AB_2218911), and p‐YAP (Ser127) (CST, #4911, RRID:AB_2218913) were used at 1:1000 as indicated.

Techniques: Western Blot, Analysis, Expressing, Control, Derivative Assay, Transplantation Assay

Journal: Acta Pharmaceutica Sinica. B

Article Title: Hepatokine FGL1 drives endothelial injury and atherogenesis via integrin β 1-mediated endothelial–mesenchymal transition

doi: 10.1016/j.apsb.2026.06.005

Figure Lengend Snippet: FGL1 promotes EndoMT by activating FAK/ERK and SMAD signaling cascades sequentially downstream of integrin β 1 activation. (A) Western blot analysis of the time-dependent activation effects of FGL1 on FAK, ERK and Smad signaling molecules in endothelial cells; n = 3–4. (B) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and ERK (PD98059) on FGL1-induced FAK and ERK activation and EndoMT; n = 3–6. (C) Western blot analysis of the effects of small molecule Smad2/3 inhibitor (SB431542) on FGL1-induced Smad2/3 activation and EndoMT; n = 3–4. (D) Western blot analysis of the effects of small molecule inhibitors of FAK (GSK2256098) and Smad2/3 (SB431542) on FGL1-induced upregulation of pro-EndoMT transcriptional factors; n = 3. (E) The administration strategy of recombinant FGL1 protein (15 μg/kg) in Apoe −/− mice. (F) Quantification of plasma FGL1 protein concentration through ELISA analysis; n = 8. (G–I) Immunofluorescence analysis of phospho-FAK(Tyr397), phospho-ERK1/2(Tyr202/204) and phospho-Smad2/3(Ser465/467) in aortic root of atherosclerotic mice; Scale bar: 50 μm; n = 6. Data are presented as mean ± SEM. Each dot represents an average of three technical replicates of a dish of cells or a mouse.

Article Snippet: In the other series of experiments, HUVECs were pretreated with FAK inhibitor GSK2256098 (#T2281, Topscience), MEK inhibitor PD98059 (#T2623, Topscience), ALK inhibitor SB431542 (#T1726, Topscience) for 30 min, or pretreated with Integrin β 1 antibody (#MAB17781, R&D Systems) for 6 h, followed by treatment with FGL1.

Techniques: Activation Assay, Western Blot, Recombinant, Clinical Proteomics, Protein Concentration, Enzyme-linked Immunosorbent Assay, Immunofluorescence